Share Twitter LinkedIn Facebook Email Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center reviews early trial data of immunotherapy agents for treatment of small cell lung cancer (SCLC). Advertisement
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read